Please login (Members) to view content or
(Nonmembers) this article.
0

No votes yet

CNE Article

CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia


Colleen Callahan
Diane Baniewicz
Beth Ely
CJON 2017, 21(2), 22-28 DOI: 10.1188/17.CJON.S2.22-28

Background: Immunotherapy provides a promising treatment option for children and adolescents with refractory or relapsed acute lymphoblastic leukemia (ALL). 


Objectives: This article presents a hospital’s experience with providing chimeric antigen receptor (CAR) T-cell therapy, followed by a detailed discussion of the trajectory of treatment provided for pediatric patients and their families.


Methods: Clinical experience in delivering care to pediatric patients undergoing CAR T-cell therapy is described. Care coordination, patient and family assessment and education, and post–CAR T-cell infusion monitoring are presented. 


Findings: Of 59 patients having been treated with CAR T-cell therapy at the authors’ institution, 93% had a complete response at day 28. The 12-month relapse-free survival rate is 55%. A multidisciplinary team of skilled clinicians is recommended to support patient and family needs throughout screening, treatment, and follow-up while coordinating care with the referring oncologist.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or